Phocas Financial Corp. Has $596,000 Stock Position in Sotera Health (NASDAQ:SHC)

Phocas Financial Corp. trimmed its holdings in shares of Sotera Health (NASDAQ:SHC - Free Report) by 85.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 43,593 shares of the company's stock after selling 248,619 shares during the period. Phocas Financial Corp.'s holdings in Sotera Health were worth $596,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Geode Capital Management LLC raised its holdings in shares of Sotera Health by 19.4% during the third quarter. Geode Capital Management LLC now owns 2,755,391 shares of the company's stock worth $46,026,000 after purchasing an additional 447,186 shares during the period. Maven Securities LTD acquired a new stake in shares of Sotera Health during the third quarter worth $1,670,000. Cerity Partners LLC acquired a new stake in shares of Sotera Health during the third quarter worth $1,489,000. Neo Ivy Capital Management acquired a new stake in shares of Sotera Health in the 3rd quarter worth about $720,000. Finally, Barclays PLC increased its holdings in shares of Sotera Health by 169.8% in the 3rd quarter. Barclays PLC now owns 473,597 shares of the company's stock worth $7,909,000 after acquiring an additional 298,085 shares during the period. 91.03% of the stock is owned by institutional investors and hedge funds.

Sotera Health Price Performance

Sotera Health stock traded up $0.19 during trading hours on Friday, hitting $12.47. 1,816,518 shares of the company traded hands, compared to its average volume of 979,003. The firm has a market cap of $3.53 billion, a P/E ratio of 49.88 and a beta of 1.91. The company has a quick ratio of 2.61, a current ratio of 2.88 and a debt-to-equity ratio of 4.91. The firm's 50-day simple moving average is $13.45 and its two-hundred day simple moving average is $14.51. Sotera Health has a 1-year low of $10.71 and a 1-year high of $17.08.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $17.00 price objective on shares of Sotera Health in a report on Thursday, November 21st. The Goldman Sachs Group assumed coverage on shares of Sotera Health in a report on Friday, December 6th. They issued a "neutral" rating and a $14.00 price objective on the stock. Citigroup increased their price objective on shares of Sotera Health from $18.00 to $20.00 and gave the stock a "buy" rating in a report on Wednesday, November 6th. Finally, Barclays dropped their price objective on shares of Sotera Health from $17.00 to $16.00 and set an "overweight" rating on the stock in a report on Friday. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $15.92.

Sotera Health Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.